How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/renal-radiation-exposure-from-lutetium-177lu-oxodotreotide.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Renal radiation exposure from Lutetium (177Lu) oxodotreotide — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Renal radiation exposure from Lutetium (177Lu) oxodotreotide (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Renal radiation exposure from Lutetium (177Lu) oxodotreotide, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	Line of therapy	First approval
R-Gene 10	ARGININE	Pfizer	arginine hydrochloride	Nitric oxide synthase, inducible		1973-01-01
L-Lysine	LYSINE	Advanced Accelerator Applications	lysine	Glutathione reductase, mitochondrial

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Advanced Accelerator Applications · 1 drug in Renal radiation exposure from Lutetium (177Lu) oxodotreotide
Pfizer · 1 drug in Renal radiation exposure from Lutetium (177Lu) oxodotreotide

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Renal radiation exposure from Lutetium (177Lu) oxodotreotide:

Cite this brief

Drug Landscape (2026). Renal radiation exposure from Lutetium (177Lu) oxodotreotide — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/renal-radiation-exposure-from-lutetium-177lu-oxodotreotide. Accessed 2026-06-10.

Renal radiation exposure from Lutetium (177Lu) oxodotreotide full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing